Your browser doesn't support javascript.
loading
Long-term Tolvaptan Treatment of Autosomal Dominant Polycystic Kidney Disease in Korea
Electrolytes & Blood Pressure ; : 23-26, 2018.
Article in English | WPRIM | ID: wpr-739604
ABSTRACT
A 22-year-old male patient was diagnosed with autosomal dominant polycystic kidney disease (ADPKD). He received conservative treatment with an angiotensin-converting enzyme inhibitor. Two years later, oral therapy, consisting of 60 mg tolvaptan per day, was initiated. Compared with height-adjusted total kidney volume, the rate of kidney growth reduced significantly from 7.33% to 0.66% annually, since commencement of the tolvaptan therapy. The liver enzyme profile and serum sodium level and osmolality were constantly within normal ranges. In Korea, this is the first reported case of a patient with ADPKD who received tolvaptan treatment for more than 1 year. This case demonstrates that long-term tolvaptan treatment appears to be safe, well tolerated, and effective for ADPKD.
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: Osmolar Concentration / Reference Values / Sodium / Polycystic Kidney, Autosomal Dominant / Kidney / Korea / Liver Limits: Humans / Male Country/Region as subject: Asia Language: English Journal: Electrolytes & Blood Pressure Year: 2018 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Osmolar Concentration / Reference Values / Sodium / Polycystic Kidney, Autosomal Dominant / Kidney / Korea / Liver Limits: Humans / Male Country/Region as subject: Asia Language: English Journal: Electrolytes & Blood Pressure Year: 2018 Type: Article